FDA approves Novo Nordisk's diabetes drug Ozempic for chronic kidney disease, expanding its use
1. FDA approved Ozempic for chronic kidney disease and diabetes management. 2. Ozempic reduced severe kidney outcomes by 24% in diabetic patients. 3. Approval may transform treatments for chronic kidney disease affecting 37 million Americans. 4. Novo Nordisk faces competition from Eli Lilly for diabetes treatments. 5. Clinical trials showed reduced cardiovascular risks in patients using Ozempic.